World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
32309
World Ranking
8973
National Ranking
309

Carlo Pozzilli publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Carlo Pozzilli sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 538 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Carlo Pozzilli D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Carlo Pozzilli sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Carlo Pozzilli is affiliated with Sapienza University of Rome in Italy. Their research work primarily focuses on multiple sclerosis and related neurological disorders, with a significant number of publications in the field of medicine.

The main fields of study for Carlo Pozzilli include:

  • Medicine

Within this broad field, their subfields of research cover:

  • Pathology and Forensic Medicine
  • Neurology
  • Oncology
  • Rheumatology
  • Molecular Biology

The central topics explored in their work encompass:

  • Multiple Sclerosis Research Studies
  • Peripheral Neuropathies and Disorders
  • Polyomavirus and related diseases
  • Rheumatoid Arthritis Research and Therapies
  • Immunotherapy and Immune Responses
  • Acute Lymphoblastic Leukemia research
  • Autoimmune and Inflammatory Disorders Research

Carlo Pozzilli's frequent co-authors reveal a collaborative research environment and include:

  • Massimo Filippi
  • Francesco Patti
  • Antonio Ianniello
  • María Trojano
  • Maria Pia Amato

Their most common publication venues, indicating where a significant portion of their research has appeared, are:

  • Journal of Neurology
  • Neurology
  • Multiple Sclerosis Journal
  • Multiple Sclerosis and Related Disorders
  • Journal of Neurology Neurosurgery & Psychiatry

Among recent papers, several notable publications include:

  • Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study (2021), JAMA Neurology
  • Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion (2022), Journal of Neurology
  • Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder (2023), Annals of Neurology
  • Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies (2021), Therapeutic Advances in Neurological Disorders
  • Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial (2020), The Lancet Neurology

Best Publications

  • Defining the clinical course of multiple sclerosis: The 2013 revisions

    Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter

  • Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography.

    R. S J Frackowiak;C. Pozzilli;N. J. Legg;G. H. Du Boulay

  • Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo- controlled, randomized phase II trial

    Ludwig Kappos;Giancarlo Comi;Hillel Panitch;Joel Oger

  • A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

    A. Novotna;J. Mares;S. Ratcliffe;I. Novakova

  • Diffusion-weighted imaging tractography-based parcellation of the human lateral premotor cortex identifies dorsal and ventral subregions with anatomical and functional specializations.

    Valentina Tomassini;Saad Jbabdi;Johannes C. Klein;Timothy E. J. Behrens

  • Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

    Ludwig Kappos;David Bates;Gilles Edan;Mefkûre Eraksoy

  • Multiple sclerosis in childhood: clinical features of 149 cases.

    A. Ghezzi;V. Deplano;J. Faroni;MG Grasso

  • fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis.

    Caterina Mainero;Francesca Caramia;Carlo Pozzilli;Angela Pisani

  • Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

    E Millefiorini;C Gasperini;C Pozzilli;F D'Andrea

  • Cognitive and psychosocial features of childhood and juvenile MS

    M. P. Amato;B. Goretti;A. Ghezzi;S. Lori

  • Progressing Neurological Deficit Secondary to Acute Ischemic Stroke: A Study on Predictability, Pathogenesis, and Prognosis

    Danilo Toni;Marco Fiorelli;Mara Gentile;Stefano Bastianello

  • The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis

    Pd Molyneux;L Kappos;C Polman;C Pozzilli

  • Assessing walking disability in multiple sclerosis

    Bernd C. Kieseier;Carlo Pozzilli

  • Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

    P. S. Sørensen;F. Deisenhammer;P. Duda;R. Hohlfeld

  • Interferon beta-1b in secondary progressive MS - A combined analysis of the two trials

    Ludwig Kappos;B. Weinshenker;C. Pozzilli;A. J. Thompson

  • Cognitive and psychosocial features in childhood and juvenile MS Two-year follow-up

    M. P. Amato;B. Goretti;A. Ghezzi;S. Lori

  • A mechanism-based classification of pain in multiple sclerosis.

    A. Truini;P. Barbanti;C. Pozzilli;G. Cruccu

  • Cortical motor reorganization after a single clinical attack of multiple sclerosis

    Patrizia Pantano;Gian Domenico Iannetti;Francesca Caramia;Caterina Mainero

  • Fatigue in MS is associated with specific clinical features.

    C. Colosimo;E. Millefiorini;M. G. Grasso;F. Vinci

  • Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial

    Otto R Hommes;Per S Sørensen;Franz Fazekas;Monika Maas Enriquez

Frequent Co-Authors

Maria Trojano
Maria Trojano University of Bari Aldo Moro
Maria Pia Amato
Maria Pia Amato University of Florence
Giancarlo Comi
Giancarlo Comi Vita-Salute San Raffaele University
Massimo Filippi
Massimo Filippi Vita-Salute San Raffaele University
Diego Centonze
Diego Centonze University of Rome Tor Vergata
Eva Havrdova
Eva Havrdova Charles University
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Vincenzo Morra
Vincenzo Morra University of Naples Federico II
Patrick Vermersch
Patrick Vermersch University of Lille

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens up a wide range of allied health and management career options. For those interested in hospital operations or leadership, earning a healthcare administration degree online offers the flexibility to build skills in management, finance, and policy while balancing other commitments.

Nursing professionals looking to advance can take advantage of asn to np pathways. These bridge programs help nurses move from an associate’s degree to a nurse practitioner role, often through accelerated and fully online options.

Nutrition and wellness are also growing fields within healthcare. Earning a nutritionist online degree prepares students to work in clinical, community, or private practice settings focused on diet, health, and lifestyle management.

If you are seeking leadership roles in health systems, consider the range of online mha programs cahme accredited, which ensure a high standard of curriculum recognized nationwide.

Best Scientists Citing Carlo Pozzilli

Trending Scientists

Recently Published Articles